Skip to main content

AI news

Boltz announces $110 million Series A for molecular design AI

Boltz announced a $110 million Series A led by Bessemer Venture Partners to invest in compute, data and its molecular design tools. The company says six top-20 pharma companies are partners and reports growth in usage; those operating claims come from Boltz and are not proof of drug-development outcomes.

Primary source · November 18, 2026

Opens Boltz in a new tab. Read it there before you rely on the summary above.

Read the original

Free, email only

Unlock the full brief free.

  • What to check before you trust this story, written down
  • Each verified source, with why it matters and who published it
  • A note whenever a source has been withdrawn
  • Thirty days of stories to browse, not seven

Continuing subscribes the email on that account to Work Worth Doing, my newsletter, the same as the form below, and unlocks every free tool in this browser. We only receive your email address. Unsubscribe in one click.

This is not an account: there is no password, and the unlock is a cookie in this browser. You also join Work Worth Doing, Demetri Panici's newsletter, every week: what I built and what changed in AI. We'll email you a link to confirm, and you can unsubscribe in one click. The same signup unlocks every free tool on the site. How your email is handled.

Already subscribed? Enter the same email to unlock this browser. You won't be signed up twice.